Shattuck Labs shows a wide risk/reward asymmetry and large analyst-implied upside, but quality sits far below the engine's floor on extreme cash burn and the stock is technically overbought.
Thesis pillars
- Large Analyst Upside→Stable
- Wide Risk Reward Asymmetry→Stable
- Quality Floor Extreme Cash Burn→Stable
- +1 more pillar — see the Why tab for full reasoning
Shattuck Labs, Inc. (STTK) Stock Analysis
Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $6.88: Quality below floor (2.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10 and A.R:R 5.8:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality.
Shattuck Labs is a clinical-stage biotechnology company developing DR3-blocking antibodies for inflammatory and immune-mediated diseases, led by SL-325, a monoclonal antibody designed to block the DR3/TL1A signaling pathway implicated in ulcerative colitis and Crohn's disease.... Read more
Sell if holding. Engine safety override at $6.88: Quality below floor (2.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10 and A.R:R 5.8:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.9/10, moderate confidence.
Passes 7/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity 38d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
About Shattuck Labs, Inc.
About Shattuck Labs, Inc.
Shattuck Labs' lead product candidate, SL-325, a DR3-blocking monoclonal antibody, is advancing through a Phase 1 trial in healthy volunteers that the company expects to complete in the second quarter of 2026, ahead of a randomized, placebo-controlled Phase 2 trial in Crohn's disease patients planned for the third quarter of 2026. The company has generated no product revenue and is also developing SL-425, a half-life-extended version of SL-325, alongside preclinical DR3-targeting bispecific antibodies.
Shattuck's strategy is to block the DR3 receptor rather than its ligand TL1A, arguing that DR3's stable expression on lymphocytes allows more complete pathway blockade than the TL1A-blocking antibodies tulisokibart, duvakitug, and afimkibart, each of which has already shown 23% to 28% placebo-adjusted clinical remission rates in third-party Phase 2 trials for ulcerative colitis and Crohn's disease. Those same TL1A-blocking antibodies have also shown anti-drug antibody formation in more than 64% of treated subjects in third-party trials, a side effect Shattuck says its DR3-targeting mechanism is designed to avoid. The inflammatory bowel disease market Shattuck is targeting is projected to grow from $23 billion in 2023 to $34 billion by 2030.
Show full overview
Shattuck's near-term value depends entirely on a single mechanism-of-action bet across its whole pipeline: SL-325, SL-425, and the company's preclinical bispecific antibody candidates are all built around blocking the same DR3 receptor, so a safety or efficacy failure specific to DR3 blockade — rather than to any one molecule — could compromise every program at once. The company's own comparison data shows two third-party TL1A-directed bispecific antibodies, AMG966 and RO7837195, produced nearly 100% anti-drug antibody formation after a single dose in Phase 1 trials, underscoring how immunogenicity failures in this pathway have historically hit entire modalities rather than individual molecules.
See also: Healthcare · Biotechnology
From Shattuck Labs, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineSL-325 / DR3 platform10-K Item 1: 'our lead program, SL-325, a potentially first-in-class DR3 blocking antibody'
Material Events(8-K, last 90d)
- 2026-06-02Item 5.02LOWStockholders approved an amendment and restatement of the 2020 Equity Incentive Plan at the May 28, 2026 Annual Meeting, increasing shares available by 1,691,082 and extending the plan's term to March 23, 2036; a routine equity-plan action, not a departure.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $6.88: Quality below floor (2.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10 and A.R:R 5.8:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $6.40. Score 5.9/10, moderate confidence.
Take-profit target: $12.90 (+87.5% upside). Prior stop was $6.40. Stop-loss: $6.40.
Concentration risk — Pipeline: SL-325 / DR3 platform; Quality below floor (2.0 < 4.0).
Shattuck Labs, Inc. trades at a P/E of N/A (forward -14.0). TrendMatrix value score: 9.0/10. Verdict: Sell.
14 analysts cover STTK with a consensus score of 4.2/5. Average price target: $15.
What does Shattuck Labs, Inc. do?Shattuck Labs is a clinical-stage biotechnology company developing DR3-blocking antibodies for inflammatory and...
Shattuck Labs is a clinical-stage biotechnology company developing DR3-blocking antibodies for inflammatory and immune-mediated diseases, led by SL-325, a monoclonal antibody designed to block the DR3/TL1A signaling pathway implicated in ulcerative colitis and Crohn's disease. SL-325 is in an ongoing Phase 1 trial in healthy volunteers expected to complete enrollment in the second quarter of 2026, ahead of a planned Phase 2 trial in Crohn's disease patients in the third quarter of 2026. The company has generated no product revenue to date.